Longeveron Inc., a clinical-stage biotech company specializing in cellular therapies for rare pediatric and aging-related conditions, will release its Q1 2026 financial results on May 13 after market close. The company will also provide a business update and hold a conference call and webcast at 4:30 p.m. ET the same day. Longeveron's lead product, laromestrocel, targets multiple serious diseases and has received several FDA designations, highlighting its potential. Investors can expect updates on ongoing trials and company progress during the call.
Sierra Bancorp reported Q2 earnings per share (EPS) of $0.77, below analyst expectations of $0.89, and revenue of $38.98 million, missing the forecast of $39.59 million. The EPS slightly declined from $0.78 a year ago, indicating a small year-over-ye...
Navitas Semiconductor, a maker of AI data center power chips, has seen its stock fall 40% this month, making its upcoming earnings report crucial. Analysts expect a loss of $0.04 per share and revenue near $10 million, reflecting a 31.3% decline from...
Michelin has published its financial report for the first half of 2026, which is now accessible on its official website. The report has also been officially filed with the French Autorité des Marchés Financiers (AMF), ensuring regulatory compliance. ...
Michelin has published and filed its half-year financial report as of June 30, 2026, with the French financial regulator AMF. The report and the presentation of the 2026 half-year results are accessible on Michelin's official website. This disclosure...
In the first half of 2026, Michelin saw an increase in segment operating income at constant scope and exchange rates, alongside a rise in free cash flow before mergers and acquisitions. The company has confirmed its financial guidance for the full ye...
